CA2843896A1 - Collagen 7 and related methods - Google Patents
Collagen 7 and related methods Download PDFInfo
- Publication number
- CA2843896A1 CA2843896A1 CA2843896A CA2843896A CA2843896A1 CA 2843896 A1 CA2843896 A1 CA 2843896A1 CA 2843896 A CA2843896 A CA 2843896A CA 2843896 A CA2843896 A CA 2843896A CA 2843896 A1 CA2843896 A1 CA 2843896A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- collagen
- functional fragment
- encodes
- express
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 121
- 108010035532 Collagen Proteins 0.000 title claims abstract description 121
- 229920001436 collagen Polymers 0.000 title claims abstract description 120
- 238000000034 method Methods 0.000 title claims abstract description 61
- 239000012634 fragment Substances 0.000 claims abstract description 82
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 67
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 30
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 30
- 239000013598 vector Substances 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims description 149
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 44
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 102100039662 Xaa-Pro dipeptidase Human genes 0.000 claims description 34
- 108010066823 proline dipeptidase Proteins 0.000 claims description 34
- 102000051366 Glycosyltransferases Human genes 0.000 claims description 31
- 108700023372 Glycosyltransferases Proteins 0.000 claims description 31
- 239000013604 expression vector Substances 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 108020004705 Codon Proteins 0.000 claims description 23
- 239000004471 Glycine Substances 0.000 claims description 22
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 239000002609 medium Substances 0.000 claims description 15
- 239000001963 growth medium Substances 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 101000606589 Homo sapiens Xaa-Pro dipeptidase Proteins 0.000 claims description 7
- 102000003838 Sialyltransferases Human genes 0.000 claims description 7
- 108090000141 Sialyltransferases Proteins 0.000 claims description 7
- 102000053855 human PEPD Human genes 0.000 claims description 7
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 5
- 229920002684 Sepharose Polymers 0.000 claims description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 4
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 4
- 230000001143 conditioned effect Effects 0.000 claims description 4
- 210000004748 cultured cell Anatomy 0.000 claims description 4
- 238000005571 anion exchange chromatography Methods 0.000 claims description 3
- 102000004357 Transferases Human genes 0.000 claims description 2
- 108090000992 Transferases Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 230000003381 solubilizing effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 23
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 21
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 21
- 239000000872 buffer Substances 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 102000004510 Collagen Type VII Human genes 0.000 description 10
- 108010017377 Collagen Type VII Proteins 0.000 description 10
- 102000001214 HSP47 Heat-Shock Proteins Human genes 0.000 description 9
- 108010055039 HSP47 Heat-Shock Proteins Proteins 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 108010050808 Procollagen Proteins 0.000 description 8
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 238000004873 anchoring Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 108020003519 protein disulfide isomerase Proteins 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 108010023005 oxoglutarate translocator Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 238000003306 harvesting Methods 0.000 description 5
- 238000003259 recombinant expression Methods 0.000 description 5
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 4
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108091006629 SLC13A2 Proteins 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 108010048032 cyclophilin B Proteins 0.000 description 3
- -1 e.g. Proteins 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 108010044156 peptidyl-prolyl cis-trans isomerase b Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 239000012614 Q-Sepharose Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000486679 Antitype Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000611202 Homo sapiens Peptidyl-prolyl cis-trans isomerase B Proteins 0.000 description 1
- 101001072202 Homo sapiens Protein disulfide-isomerase Proteins 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101710171640 Xaa-Pro dipeptidase Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 125000003508 trans-4-hydroxy-L-proline group Chemical group 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/13—Dipeptidases (3.4.13)
- C12Y304/13009—Xaa-Pro dipeptidase (3.4.13.9) i.e. prolidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
- C12Y114/11002—Procollagen-proline dioxygenase (1.14.11.2), i.e. proline-hydroxylase
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161514796P | 2011-08-03 | 2011-08-03 | |
| US61/514,796 | 2011-08-03 | ||
| PCT/US2012/049553 WO2013020064A1 (en) | 2011-08-03 | 2012-08-03 | Collagen 7 and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2843896A1 true CA2843896A1 (en) | 2013-02-07 |
Family
ID=47629706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2843896A Abandoned CA2843896A1 (en) | 2011-08-03 | 2012-08-03 | Collagen 7 and related methods |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9676837B2 (enExample) |
| EP (1) | EP2753704A4 (enExample) |
| JP (2) | JP2014524241A (enExample) |
| KR (1) | KR20140054160A (enExample) |
| CN (2) | CN103842517A (enExample) |
| AU (2) | AU2012289916B2 (enExample) |
| BR (1) | BR112014002546A2 (enExample) |
| CA (1) | CA2843896A1 (enExample) |
| MX (1) | MX351565B (enExample) |
| WO (1) | WO2013020064A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60138535D1 (de) | 2000-02-04 | 2009-06-10 | Children S Hospital Res Founda | Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten |
| KR101742346B1 (ko) | 2010-04-23 | 2017-06-15 | 시나게바 바이오파르마, 코포레이션 | 리소솜 축적병 효소 |
| BR122019021757B1 (pt) | 2010-09-09 | 2020-12-08 | Alexion Pharmaceuticals, Inc | composição farmacêutica para tratamento de um paciente humano sofrendo de uma deficiência de lipase ácida lisossomal (lal) |
| EP2675472A4 (en) | 2011-02-15 | 2014-09-17 | Synageva Biopharma Corp | METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE |
| WO2012149136A1 (en) | 2011-04-26 | 2012-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Production and delivery of a stable collagen |
| KR102415811B1 (ko) | 2014-01-31 | 2022-07-04 | 팩터 바이오사이언스 인크. | 핵산 제조 및 송달을 위한 방법 및 산물 |
| US10227394B2 (en) | 2014-04-08 | 2019-03-12 | University Of Southern California | Polypeptide compositions with type VII collagen fibronectin type III-like repeats and treatment methods for wound closure and healing |
| KR102204367B1 (ko) * | 2014-07-16 | 2021-01-19 | 주식회사 엘지생활건강 | 피부 주름 개선용 화장료 조성물 |
| US11241505B2 (en) | 2015-02-13 | 2022-02-08 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| GB201601571D0 (en) * | 2016-01-28 | 2016-03-16 | Nordic Bioscience As | Collagen type Vll alpha 1 assay |
| CA3015685A1 (en) | 2016-03-16 | 2017-09-21 | Phoenix Tissue Repair, Inc. | Methods of purifying collagen 7 |
| IL264439B2 (en) | 2016-08-17 | 2024-08-01 | Factor Bioscience Inc | non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment |
| US11028146B2 (en) * | 2017-09-22 | 2021-06-08 | Modern Meadow, Inc. | Recombinant yeast strains |
| US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
| CN109022464A (zh) * | 2018-07-02 | 2018-12-18 | 西安巨子生物基因技术股份有限公司 | 重组人源型胶原蛋白的羟基化方法 |
| AU2020248453A1 (en) * | 2019-03-27 | 2021-10-28 | Phoenix Tissue Repair, Inc. | Systems and methods for producing collagen 7 compositions |
| GB2597416A (en) | 2019-04-12 | 2022-01-26 | Geltor Inc | Recombinant elastin and production thereof |
| CA3145425A1 (en) | 2019-07-03 | 2021-01-07 | Factor Bioscience Inc. | Cationic lipids and uses thereof |
| US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| EP4093761A4 (en) | 2020-01-24 | 2024-04-17 | Geltor, Inc. | Animal-free dietary collagen |
| KR20240004264A (ko) * | 2021-03-04 | 2024-01-11 | 젤라텍, 인크. | 배양된 동물 세포로부터의 콜라겐을 사용한 재료의 제조 방법 |
| US20240424065A1 (en) | 2021-10-12 | 2024-12-26 | Phoenix Tissue Repair, Inc. | Collagen 7 protein replacement therapy |
| CN117143223B (zh) * | 2022-08-23 | 2024-03-08 | 山西锦波生物医药股份有限公司 | 一种生物合成人体结构性材料的制备方法 |
| CN116854807A (zh) * | 2023-07-26 | 2023-10-10 | 浙江大学 | 一种重组人源ⅶ型胶原蛋白及其制备方法与应用 |
| CN120137008B (zh) * | 2025-03-18 | 2025-09-26 | 广东普言生物科技有限公司 | 一种重组Ⅶ型胶原蛋白Pro.C7及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020142391A1 (en) * | 1991-06-12 | 2002-10-03 | Kivirikko Kari I. | Synthesis of human procollagens and collagens in recombinant DNA systems |
| AU6181300A (en) | 1999-07-29 | 2001-02-19 | Helix Research Institute | Liver cancer-associated genes |
| US7026463B2 (en) | 1999-08-13 | 2006-04-11 | Matthew Glenn | Polynucleotides and polypeptides, materials incorporating them and methods for using them |
| AU1591701A (en) * | 1999-11-12 | 2001-06-06 | Fibrogen, Inc. | Recombinant gelatins |
| CN1552889A (zh) * | 2003-12-18 | 2004-12-08 | 四川铭让生物科技有限公司 | 制备胶原蛋白和胶原多肽的方法及其用途 |
| JP4490498B2 (ja) * | 2008-09-30 | 2010-06-23 | 新田ゼラチン株式会社 | 疾病抑制剤 |
| WO2012149136A1 (en) * | 2011-04-26 | 2012-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Production and delivery of a stable collagen |
-
2012
- 2012-08-03 CN CN201280047084.3A patent/CN103842517A/zh active Pending
- 2012-08-03 MX MX2014001383A patent/MX351565B/es active IP Right Grant
- 2012-08-03 WO PCT/US2012/049553 patent/WO2013020064A1/en not_active Ceased
- 2012-08-03 EP EP12820654.7A patent/EP2753704A4/en not_active Withdrawn
- 2012-08-03 JP JP2014524112A patent/JP2014524241A/ja active Pending
- 2012-08-03 AU AU2012289916A patent/AU2012289916B2/en not_active Ceased
- 2012-08-03 BR BR112014002546A patent/BR112014002546A2/pt not_active Application Discontinuation
- 2012-08-03 KR KR1020147005544A patent/KR20140054160A/ko not_active Ceased
- 2012-08-03 US US14/236,403 patent/US9676837B2/en active Active
- 2012-08-03 CA CA2843896A patent/CA2843896A1/en not_active Abandoned
- 2012-08-03 CN CN201711271805.XA patent/CN108165593A/zh active Pending
-
2017
- 2017-09-07 JP JP2017171852A patent/JP2017209117A/ja not_active Abandoned
- 2017-11-02 AU AU2017254910A patent/AU2017254910A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017209117A (ja) | 2017-11-30 |
| KR20140054160A (ko) | 2014-05-08 |
| BR112014002546A2 (pt) | 2017-03-14 |
| EP2753704A4 (en) | 2015-07-08 |
| EP2753704A1 (en) | 2014-07-16 |
| JP2014524241A (ja) | 2014-09-22 |
| US20150011733A1 (en) | 2015-01-08 |
| MX351565B (es) | 2017-10-19 |
| AU2017254910A1 (en) | 2017-11-23 |
| CN108165593A (zh) | 2018-06-15 |
| WO2013020064A1 (en) | 2013-02-07 |
| CN103842517A (zh) | 2014-06-04 |
| US9676837B2 (en) | 2017-06-13 |
| AU2012289916B2 (en) | 2017-08-03 |
| MX2014001383A (es) | 2014-08-26 |
| AU2012289916A1 (en) | 2014-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012289916B2 (en) | Collagen 7 and related methods | |
| US20250122251A1 (en) | Expression in mammalian cells with signal peptide | |
| CN100587073C (zh) | 人成纤维细胞生长因子-21的重组表达 | |
| CN104704126B (zh) | 在酵母表达系统中利用人内质网分子伴侣蛋白天然信号序列产生天然重组的分泌的人内质网分子伴侣蛋白 | |
| CN108610398B (zh) | 一段功能序列及在分泌蛋白表达中的应用 | |
| AU2023289270A1 (en) | N-terminal and/or c-terminal cleaved soluble ph20 polypeptide and use thereof | |
| Nasrabadi et al. | Inclusion body expression and refolding of recombinant bone morphogenetic protein-2 | |
| Akuta et al. | Expression of bioactive soluble human stem cell factor (SCF) from recombinant Escherichia coli by coproduction of thioredoxin and efficient purification using arginine in affinity chromatography | |
| CN112500495A (zh) | 一种elp-ⅲ型胶原蛋白的纯化方法及应用 | |
| CN119841961A (zh) | 一种胶原蛋白融合多肽及其用途与制备方法 | |
| CN103911383A (zh) | 适于家蚕丝腺表达的改造人酸性成纤维细胞生长因子基因及其表达系统和应用 | |
| CN121108305A (zh) | 一种重组人源xvii小分子型胶原蛋白及其制备方法与应用 | |
| US20180002401A1 (en) | Collagen 7 and related methods | |
| SG11202109738QA (en) | Recombinant ccn domain proteins and fusion proteins | |
| Su-Xia et al. | Cloning and expression of a new rat procarboxypeptidase B gene in Escherichia coli and purification of recombination carboxypeptidase B | |
| KR101871805B1 (ko) | 재조합 상피세포성장인자의 제조방법 | |
| EP2633058B1 (en) | Method for mass production of factor vii/viia | |
| CN109384838B (zh) | 三重转录因子及其在哺乳动物蛋白表达系统的应用 | |
| CN116217699B (zh) | 一种高效表达羊生长激素的方法 | |
| Cheng et al. | New Strategy for Expression of Recombinant Human Prolyl-4-Hydroxylase in Pichia pastoris | |
| CN104130308A (zh) | 一种蛋白质定点peg修饰的方法及所得peg修饰的蛋白质 | |
| KR20090058219A (ko) | 고농도 우레아하에서 안정된 활성을 갖는 디유비퀴틸레이팅효소를 이용한 펩티드의 제조방법 | |
| Cheng YaTing et al. | New strategy for expression of recombinant human prolyl-4-hydroxylase in Pichia pastoris. | |
| Suzuki et al. | Functional expression and characterization of a Xenopus laevis peptidylglycine α‐amidating monooxygenase, AE‐II, in insect‐cell culture | |
| WO2026082137A1 (zh) | 糜蛋白酶原及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170724 |
|
| FZDE | Dead |
Effective date: 20191203 |